eISSN: 1644-4124
ISSN: 1426-3912
Central European Journal of Immunology
Current issue Archive Manuscripts accepted About the journal Abstracting and indexing Subscription Contact Instructions for authors
SCImago Journal & Country Rank

vol. 32

The pulmonary complications during the course of CVID

Barbara Basiewicz-Worsztynowicz, Wiesława Karnas-Kalemba, Adam Jankowski

(Centr Eur J Immunol 2007; 32 (1): 15-20)
Online publish date: 2007/04/16
Article file
- The pulmonary.pdf  [0.07 MB]
Get citation
JabRef, Mendeley
Papers, Reference Manager, RefWorks, Zotero


Common variable immunodeficiency (CVID) is characterized by abnormal humoral response, accompanied by immunoglobulin deficiency [1, 2]. Patients with CVID suffer from recurrent and often chronic infections, these can cause pulmonary changes [3, 4]. The most frequently observed CVID complications within the respiratory tract are bronchiectasis, interstitial disorder, granulomas and lymphomas [5]. Mechanisms leading to development of chronic pulmonary changes have not been thoroughly researched.
Lungs are subjected to constant contact with various antigens. Patients with CVID harbour viral and bacterial infections, which may predispose to the development of changes in the lower respiratory tract [3]. The lungs defence mechanisms eliminate foreign bodies through spontaneous, local mechanisms or through immunological reactions. Lymphoid tissue of the respiratory tract is located within the lymph nodes (such as peribronchiolar, trachea and hilar lymph nodes) as well as accumulating in lymphoid tissue, the lining the bronchi, submucosal areas, in interalveolar septa and in alveoli. Clusters of lymphoid follicles and also solitary lymphoid follicles (bronchus-associated lymphoid tissue -BALT), are frequently found within mucosa and submucosa of the respiratory tract. Most immunoglobulins found in the respiratory tract are produced locally. IgA is mainly to be found in the large bronchi, and lower airways are dominated by IgG. Other essential elements of the immune system are epithelial cells of the bronchi, with MHC class I and class II molecules on their surface. These cells also secrete chemotactic factors and antyproteases. The alveolar macrophages have several functions including phagocytosis.

Pulmonary changes associated with CVID

The reason responsible for changes in lung parenchyma during immunological disorder have not been completely explained. Pulmonary changes may be the result of either of the following: chronic presence of virus antigen or bacteria, or through cytokine activity and/or circulating lymphocytes influx. Various different genetic disorders may bring about pulmonary changes [6-8]. Parenchymal lung diseases consist of many CVID complications and are
240 times more frequent in patients with immunoglobulin deficiency than in remaining population [9]. The results of large series of 103 patients with CVID have shown, that 22% patients were diagnosed with pulmonary changes (regardless of the presence bronchiectasis) [10]. The varied syndromes appear in the lungs, in which alveoli and tissue around alveoli become inflamed by immune cells. Progression of the disease leads to disseminated infiltrates in lungs, fibrosis and lung structure remodelling. Increasing changes within the lungs lead to gas exchange disorders (especially restrictive), further to pulmonary hypertension and complications in the circulatory system.
On the basis of American Thoracic Society/ European Respiratory Society consensus (2001), thoroughly defined and classified diffuse parenchymal lung disease (DPLD) as the following: 1. DPLD of known cause e.g. drugs or association e.g. collagen vascular disease; 2. Idiopathic interstitial pneumonias; 3. Granulomatous DPLD e.g. sarcoidosis;
4. Other forms of DPLD e.g. histiocytosis X etc [11].
The relationship between dysgammaglobulinemia and interstitial lung diseases was described for the first time by Liebow and Carrington in 1973. The authors thoroughly investigated 18 cases of lymphocytic interstitial pneumonia (LIP) of which: 8 patients with hypergammaglobulinemia IgG, 4 patients with hypergammaglobulinemia IgM and
5 patients with hypogammaglobulinemia were observed [12]. Other authors obtained similar results [13, 14]. The presence of LIP in patients with common variable immunodeficiency has been well documented [15-17]. The origin of lymphoproliferation has yet to be fully investigated. Regardless of agent evoking abnormal immune responses, under observation patients with LIP have enlarged cervical, thoracic and abdominal lymph nodes [16]. Infiltration by small, mature, polyclonal lymphocytes and plasma cells diffused in lung parenchyma, as well as enlarged lymph nodes, within the lung, resemble huge lymphoid organ. Splenomegaly is often accompanied by enlarged Peyer’s patches within the intestinal wall. Occasionally cells also infiltrating other organs can be observed [18, 19]. Benign lymfoproliferative disorders are recognised in about 30% of patients with CVID. They are often accompanied by splenomegaly and lymphadenopathy. Such patients are particularly susceptible to lymphoma, when mixed B and T lymphocytes are present [20]. Other uncommon idiopathic interstitial pneumonias have also been observed in patients with CVID [21, 22].
Previous studies demonstrated, that in patients with firstly diagnosis of low immunoglobulin serum levels, the lung disease can develop or secondly immunological disorder manifestations, occurring during the course of the lung disease. Among a series of 47 patients with CVID, out of which 89% were diagnosed with following lung diseases (based on lung function and high-resolution computed tomography findings): bronchiectasis (68% of patients), asthma (15%), recurrent pneumonia (19%) and granulomatous lung disease (4%) [23]. Within the another series of 69 cases of CVID syndrome, 35% of patients had chronic respiratory symptoms (without diffuse radiographic abnormalities) and 26% had chronic respiratory symptoms and diffuse radiographic abnormalities. Results of this clinical evaluation revealed that 13 patients had syndromes referred to as granulomatous-lymphocytic interstitial lung disease, (such as: granulomatous lung disease, lymphocytic interstitial pneumonia, follicular bronchiolitis, and lymphoid hyperplasia) and 5 patients suffered from other interstitial lung diseases. This study revealed that 58% patients with CVID developed the following symptoms: non-infectious lung complications, dyspnea, splenomegaly, restrictive pulmonary physiology, consolidation, ground-glass attenuation, and reticular radiographic abnormalities, along with low CD3+ and CD8+ cell populations [24].
The observations of changes occurring in lungs are uncommon due to intravenous immunoglobulin replacement therapy. In the case series of 19 patients with CVID, the mean duration of replacement therapy was 7.5 years. Bronchiectasis were diagnosed in 58% patients and 42% had multi-lobar bronchiectasis. Chronic airflow limitation were present in 53% patients and in one case a restrictive pattern was observed [25]. In another series of 22 patients, high-resolution computed tomography (HRCT) shown pulmonary abnormalities in 21 patients (18 patients had common variable immunodeficiency). Bronchiectasis were present in 72% of patients (whereas chest radiographs revealed bronchiectasis in only 13% of patients).
A prospective 3-year follow-up showed progression in 30% of patients who were received intravenous immunoglobulin replacement therapy [1].
A large series of patients with pulmonary changes, during the course of the illness were diagnosed with immunological disorders. Among the group of 148 cases with recurrent respiratory tract infections, 19% of patients were diagnosed with hypogammaglobulinemia IgG. In 8 of patients pulmonary changes were accompanied with CVID. Within the group of patients who had CVID syndrome, the following was recognised: 2 patients with cryptogenic organising pneumonia (COP), 1 with usual interstitial pneumonia (UIP), 2 with chronic pneumonitis, 1 with bronchiolitis and fibrosis and peripheral tags in further 2 patients [9]. Other studies recognised CVID in 7 adults with respiratory diseases (6 patients – bronchiectasis; 2 patients – tuberculosis) [26].
Many cases of CVID are accompanied by noncaseating granulomas [27-30]. One of such disease coexisting with CVID syndrome is sarcoidosis. A series of well-documented medical histories of 8 patients with sarcoidosis and CVID were presented, as well as summary of the previously reported 22 cases of sarcoidosis accompanying CVID syndrome [31]. Other authors obtained similar results. In a group of 189 patients diagnosed with CVID, 17 cases of granulomatous lesions discovered in lung tissue biopsy. The length of time between finding granulomas (with or without lung disease) and the institution of treatment with immunoglobulin replacement therapy, ranged from 2 to 17 years [27].
Unfortunately, the knowledge of CVID symptoms by general practitioners, respiratory physicians and paediatricians is insufficient. Often the correct diagnosis is given only after the patient has experienced long periods suffering with lung disease. In National Institute for Tuberculosis and Lung Diseases in Warsaw between 1987-2002, 35 patients with lung disease were diagnosed with CVID. The average waiting time between symptoms and correct diagnosis has often exceeded 8 years [32]. Research into sarcoidosis revealed that in 36% of patients the first diagnosis was lung disease and later recognised CVID syndrome, ranging from 1-15 years (average of 4.7 years). In 36% of patients, sarcoidosis and CVID syndrome have been recognised concurrently [31]. In another series, diagnosis of sarcoidosis preceded CVID recognition by 2-17 years (an average 9.5 years) in 41 % of patients [27].
On the other hand, in patients with CVID syndrome, there is delay in lung disease recognition [16, 33]. In one published series, in 47% of patients with CVID syndrome the mean time between the first symptoms and actual diagnosis of lung disease was 8.7 years. The mean time difference between pulmonological and immunological diagnoses was 5 years [23]. Another series reported similar findings in 23% of patients, CVID was recognised about 3.5 years prior to diagnosis of lungs changes [27]. Among patients with sarcoidosis, in 20% of cases CVID was recognised about 4 years prior to the recognition of lung disease [31]. Other studies have concurrent findings.

Pulmonary interstitial changes
in children with CVID

Within the period of a child’s development the disease progress in the immature lungs, thus character and the process of the disease, as well as clinical importance of histological changes in lungs are different than in adults. Classification of chronic interstitial lung diseases in immunocompetent children was for the first time scientifically described by European Respiratory Society in 2004. Previous reports, even from large health service centres, focused only on a small groups of children [34]. Diffuse parenchymal lung disease (DPLD) in children was divided into 4 groups: 1.DLPD of unknown association, 2.idiopathic interstitial pneumonitis, 3.other forms of interstitial pneumonia, 4.congenital disorder. This classification did not include lung diseases in children with immunodeficiency. Thus, information about the development of the disease, diagnosis and treatment is based on these rare case reports [35].
An assessment of the value of HRCT was carried out in determining the extent and significance of lung diseases, among a large group of children with antibody deficiency disorders over a 5-year period, this showed that HRCT is useful to demonstrating the extent and severity of lung disease in diagnosis and during therapy. Among 37 children of this group, 22 had changes in computed tomography (CT) lung scans, 9 children were diagnosed with bronchiectasis. There were positive relationship between the effects of intravenous immunoglobulin replacement therapy (IVIG), along with pulmonary function tests. The researchers assessed correlation between CT scores and clinical factors, also including age at the time of diagnosis, age of CT and the progress of the lung disease [36].
The interpretation difficulties of histopathological examination of the lung tissue biopsy samples in the growth and development period are unanimously well-known
[37, 38]. The case reports presenting interstitial lung changes, particulary in children with immunodeficiency diseases, are rare. The results of histopathological examinations of lung biopsy of 27 children with interstitial lung disease revealed
2 children with diagnosis of immunological disorder:
a 12-year-old patient with CVID (the result of histopathological examination was LIP), and a 3-year-old boy with hypogammaglobulinaemia (the result of histopatological examination was follicular bronchiolitis) [38].

Clinical manifestation of the disease

The most common presentation of lung diseases during the CVID are common follow symptoms: breathlessness cough, fever, tachypnoe/dyspnoe, chest pain, perspiration, anorexia, weight loss, and difficulties in physical intensive effort. A number of patients, particularly children, are treated with the assumption that this disease is asthma. The fine crackles, lymphadenopathy, hepatosplenomegaly and later clubbing, are common symptoms in physical examination [9, 24, 31].
The recurrent and progressive course of disease caused to dyspnoe, respiratory and circulatory failure. Finally consecutive infection leads to the death of the patients.
Diagnostics of pulmonary changes during the course of CVID
The diagnosis of lung disease is based on: functional, radiological and histopathological examination of the lungs. When advanced pulmonary parenchymal changes are recognised, hypoxia is diagnosed. After a patient undergoes physical exercise further examinations can be conducted of blood gases and DLCO tests. The data reveals changes and differences between bronchoalveolar lavage (BAL) results in various lung diseases. According to the research BAL and HRCT examination provide conclusive findings when combined and compared during a process of elimination. A number of authors suggest, that new clinical markers must be found (for both diagnosis and prognosis) in order to characterise BAL cells in interstitial lung diseases [39]. Transbronchial biopsy may prove helpful only in some diseases associated with CVID. X-ray examination in patients who have CVID may reveal: bronchiectasies, interstitial changes (especially in the lower parts of lungs), enlarged hilar and/or mediastenal lymph nodes. However, X-ray are not always able to detect the presence of the disease. An X-ray with no abnormalities may be taken even when the disease is presently active [40, 33].
An essential examination of parenchymal lung diseases is high-resolution computed tomography. This disease may result in: regions of lung consolidation (especially subpleural), thickening of interlobar septa and of the airway walls, bronchiectasis, sometimes ground glass attenuation, reticular opacity and honeycombing caused by fibrosis. In patients with bronchiectasis or with symptoms of fibrosis (especially in UIP), HRTC is often the final examination confirming the diagnosis. HRCT is also helpful in both, evaluating the course of the disease as well as therapy [36]. A lung biopsy is required in almost all cases of interstitial lung disease to achieve correct diagnosis. Surgical biopsy in CVID patients has added risks and can cause complications. When a disease is well-documented in HRCT, such as pulmonary fibrosis, a biopsy is performed only in 12-20% patients [26]. However, for final clinico-pathologic diagnosis, a histological examination is necessary, if accurate diagnosis can not be established by non-invasive methods [11]. Experienced pathomorphologist should examine the lung biopsy specimen. Histological features usually reveal: cellular infiltration in interstitial lung tissue, progressive destruction of lung structure and various levels of fibrosis. Sometimes for definitive diagnosis, even immunohistochemical examination is also necessary. It is essential to differentiate between polyclonal and monoclonal cells infiltration.
We have attempted to arrange the diagnostic process in ordered stages, in patients with CVID and pulmonary complications (figure 1).


These rare case reports, serve as the source only of information regarding treatment of lung diseases accompanying CVID. The patients suffering from CVID undergo intravenous immunoglobulin replacement therapy [31, 36, 40]. In patients with accompanying pulmonary parenchymal changes it is advisable to administer prednisone (in doses of 0.5-1 mg/kg day, not exceeding 100 mg/day) [15]. In children, treatment with pulsed methylprednisolone is recommended (in doses of 10-30 mg/kg/day for three days consecutively at monthly intervals) [34]. The treatment should last for 6-12 weeks and after this period daily doses should be reduced gradually until full remission. When the recurrence of pulmonary changes are observed, immunosuppressive therapy (chlorambucil, cyclosporine) or a combination of both (prednisone and cyclosporine) is recommended [16, 33]. In a few cases where CVID accompanied sarcoidosis, IVIG therapy led to regression of pulmonary changes [41].
Due to a relatively small number of observations and wide ranges of treatments schemes, it is difficult to evaluate long-term effects of therapy. Generally, development of the disease leads to gradual destruction of lung tissue and disturbances in lung architecture. Also cases of spontaneous recovery have also been observed.


This review gives particular emphasis to pulmonary complications caused by CVID. Important clinical information has now been available concerning current diagnostic processes and disease limitation management. Patients with immunodeficiency are susceptible to severe and long-term infections. The most frequent of these, are chronic pneumonitis and bronchitis which, when recurrent, lead to bronchiectasis. The findings presented throughout this report show, that bronchiectasis are present within
68%-78% of adult patients with both CVID and chronic pneumonitis [1, 23] along with 24% of children [36]. The further progression of bronchiectasis was observed in only 30% of adult patients, who received intravenous immunoglobulin replacement therapy [1].
However, ethiology of parenchymal lung diseases associating CVID are yet not clear, the interstitial and alveoli lesions are often observed. The most frequent are interstitial lung diseases and granulomas (e.g. sarcoidosis). Considerable delay in diagnosis of the lung disease accentuated the course of CVID. The probable cause of late recognition could be due to a long drawn out diagnostic process as well as the small knowledge of specialists in this range. This results in irreversible changes in lungs, such as: bronchiecatsis, progressive derangement of alveoli architecture, fibrosis and loss of functional tissue. The prognosis is reliable so long as the diagnosis made early and further to this suitable therapy is recommended.


1. Kainulainen L, Varpula M, Liippo K, et al. (1999): Pulmonary abnormalities in patients with primary hypogammaglobulinemia. J Allergy Clin Immunol 104: 1031-1036.
2. Di Renzo M, Pasqui AL, Auteri A (2004): Common variable immunodeficiency: a review. Clin Exp Med 3: 211-217.
3. Kainulainen L, Nikoskelainen J, Vuorinen T, et al. (1999): Viruses and bacteria in bronchial samples from patients with primary hypogammaglobulinemia. Am J Respir Crit Care Med 159: 1199-1204.
4. Kokron CM, Errante PR, Barros MT, et al. (2004): Clinical and laboratory aspects of common variable immunodeficiency. An Acad Bras Cienc 76: 707-726.
5. Rossi UG, Owens CM (2005): The radiology of chronic lung disease in children. Arch Dis Child 90: 601-607.
6. Hartl D, Griese M (2005): Interstitial lung disease in children – genetic background and associated phenotypes. Respir Res 6: 32.
7. Cunningham-Rundles C, Bodian C (1999): Common variable immunodeficiency: clinical and immunological features of 248 patients. Clin Immunol 92: 34-48.
8. Buckley RH ( 2004 ): Pulmonary complications of primary immunodeficiencies. Paediatr Respir Rev 5 (Suppl A): S225-S233.
9. Popa V, Colby TV, Reich SB (2002): Pulmonary interstitial disease in Ig deficiency. Chest 122: 1594-1603.
10. Cunningham-Rundles C (1989): Clinical and immunologic analyses of 103 patients with common variable immunodeficiency. J Clin Immunol 9: 22-33.
11. American Thoracic Society, European Respiratory Society (2002): American Thoracic Society/European Respiratory Society International Multidisciplinary Consensus Classification of the Idiopathic Interstitial Pneumonias. This joint statement of the American Thoracic Society (ATS), and the European Respiratory Society (ERS) was adopted by the ATS board of directors, June 2001 and by the ERS Executive Committee, June 2001. Am J Respir Crit Care Med 165: 277-304.
12. Liebow AA, Carrington CB (1973): Diffuse pulmonary lymphoreticular infiltrations associated with dysproteinemia. Med Clin N Am 57: 809-843.
13. Strimlan CV, Rosenow EC 3rd, Weiland LH, et al. (1978): Lymphocytic interstitial pneumonitis. Review of 13 cases. Ann Intern Med 88: 616-621.
14. Koss MN, Hochholzer L, Langloss JM, et al. (1987): Lymphoid interstitial pneumonia: clinicopathological and immunopathological findings in 18 cases. Pathology 19: 178-185.
15. Kohler PF, Cook RD, Brown WR, et al. (1982): Common variable hypogammaglobulinemia with T-cell nodular lymphoid interstitial pneumonitis and B-cell nodular lymphoid hyperplasia: different lymphocyte populations with a similar response to prednisone therapy. J Allergy Clin Immunol 70: 299-305.
16. Davies CW, Juniper MC, Gray W, et al. (2000): Lymphoid interstitial pneumonitis associated with common variable hypogammaglobulinaemia treated with cyclosporin A. Thorax 55: 88-90.
17. Popa V (1988): Lymphocytic interstitial pneumonia of common variable immunodeficiency. Ann Allergy 60: 203-206.
18. Elenitoba-Johnson KS, Jaffe ES (1997): Lymphoproliferative disorders associated with congenital immunodeficiencies. Semin Diagn Pathol 14: 35-47.
19. Swierkot J, Lewandowicz-Uszynska A, Jankowski A, et al. (2005): The arthritic pathologies accompanying primary immunodeficiencies with antibody synthesis disturbances. Postepy Hig Med Dosw 59: 219-223.
20. Reichenberger F, Wyser C, Gonon M, et al. (2001): Pulmonary mucosa-associated lymphoid tissue lymphoma in a patient with common variable immunodeficiency syndrome. Respiration 68: 109-112.
21. Walker JC, O’Connell MA, Pluss JL (1997): Usual interstitial pneumonitis in a patient with common variable immunodeficiency. J Allergy Clin Immunol 99: 847-851.
22. Kaufman J, Komorowski R (1991): Bronchiolitis obliterans organizing pneumonia in common variable immunodeficiency syndrome. Chest 100: 552-553.
23. Thickett KM, Kumararatne DS, Banerjee AK, et al. (2000): Common variable immunodeficiency: A respiratory physicians perspective. Thorax 55 (Suppl 3): 41.
24. Bates CA, Ellison MC, Lynch DA, et al. (2004): Granulomatous-lymphocytic lung disease shortens survival in common variable immunodeficiency. J Allergy Clin Immunol 114: 415-421.
25. Martinez Garcia MA, de Rojas MD, Nauffal Manzur MD,
et al. (2001): Respiratory disorders in common variable immunodeficiency. Respir Med 95: 191-195.
26. Kus J, Maziarka D (1993): Common variable immunodeficiency in an adult respiratory clinic. Polish J Immunol 18: 329-333.
27. Mechanic LJ, Dikman S, Cunningham-Rundles C (1997): Granulomatous disease in common variable immunodeficiency. Ann Intern Med 127: 613-617.
28. Kenneth YT, Augustine LS, James UP (2002): A case of common variable immunodeficiency disease presenting as
a sarcoidosis mimic. Chest 122 (Suppl): 247-248.
29. Park JE, Beal I, Dilworth JP, et al. (2005): The HRCT appearances of granulomatous pulmonary disease in common variable immune deficiency. Eur J Radiol 54: 359-364.
30. Ameratunga R, Becroft DM, Hunter W (2000): The simultaneous presentation of sarcoidosis and common variable immune deficiency. Pathology 32: 280-282.
31. Fasano MB, Sullivan KE, Sarpong SB, et al. (1996): Sarcoidosis and common variable immunodeficiency. Report of 8 cases and review of the literature. Medicine (Baltimore) 75: 251-261.
32. Kuś J, Maziarka D (2003): Pierwotne niedobory odporności
w klinice chorób płuc. Acta Pneumonol Alergol Ped Supl. 1: 52.
33. Karnas-Kalemba W, Basiewicz-Worsztynowicz B, Polanska B, et al. (2007): Lung diseases in children with primary immunodeficiency. Centr Eur J Immunol 32: 1-4.
34. Clement A, ERS Task Force (2004): Task force on chronic interstitial lung disease in immunocompetent children. Eur Respir J 24: 686-697.
35. Church JA, Isaacs H, Saxon A, et al. (1981): Lymphoid interstitial pneumonitis and hypogammaglobulinemia in children. Am Rev Respir Dis 124: 491-496.
36. Manson D, Reid B, Dalal I, et al. (1997): Clinical utility of high--resolution pulmonary computed tomography in children with antibody deficiency disorders. Pediatr Radiol 27: 794-798.
37. Hacking D, Smyth R, Shaw N, et al. (2000): Idiopathic pulmonary fibrosis in infants: good prognosis with conservative management. Arch Dis Child 83: 152-157.
38. Coren ME, Nicholson AG, Goldstraw P, et al. (1999): Open lung biopsy for diffuse interstitial lung disease in children.
Eur Respir J 14: 817-821.
39. Rottoli P, Bargagli E (2003): Is bronchoalveolar lavage obsolete in the diagnosis of interstitial lung disease? Curr Opin Pulm Med 9: 418-425.
40. Sweinberg SK, Wodell RA, Grodofsky MP, et al. (1991): Retrospective analysis of the incidence of pulmonary disease in hypogammaglobulinemia. J Allergy Clin Immunol 88: 96-104.
41. Busse PJ, Razvi S, Cunningham-Rundles C (2002): Efficacy of intravenous immunoglobulin in the prevention of pneumonia in patients with common variable immunodeficiency. J Allergy Clin Immunol 109: 1001-1004.
Copyright: © 2007 Polish Society of Experimental and Clinical Immunology This is an Open Access article distributed under the terms of the Creative Commons Attribution-NonCommercial-ShareAlike 4.0 International (CC BY-NC-SA 4.0) License (http://creativecommons.org/licenses/by-nc-sa/4.0/), allowing third parties to copy and redistribute the material in any medium or format and to remix, transform, and build upon the material, provided the original work is properly cited and states its license.
Quick links
© 2019 Termedia Sp. z o.o. All rights reserved.
Developed by Bentus.
PayU - płatności internetowe